Related coverage linked through entity extraction aliases.
May 05, 2026
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
Apr 20, 2026
Nektar said extended rezpeg treatment promoted greater hair growth in severe alopecia areata and reported durable 52-week efficacy for rezpegaldesleukin in atopic dermatitis. The company said it has FDA alignment on Phase 3 design and is targeting a BLA submission by 2029.
Apr 19, 2026
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Mar 16, 2026
HCW Biologics regained compliance with Nasdaq listing rules and completed a follow-on offering priced at $0.6055 per unit to raise approximately $1.5 million for clinical development of immunotherapies targeting chronic inflammation.
Mar 14, 2026
Nektar Therapeutics is advancing its immunology pipeline with plans to initiate Phase 3 trials for REZPEG in atopic dermatitis next quarter, following positive Phase 2b results. The company recently completed a large equity raise to support its regulatory T cell-focused programs.
Mar 13, 2026
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
Mar 04, 2026
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
Feb 14, 2026
Nektar Therapeutics completed a $460 million public offering on February 13, 2026, selling 7.6 million shares of common stock and pre-funded warrants. The clinical-stage biotechnology company is developing immunotherapy treatments for autoimmune diseases.
